A Double Blind, Placebo Controlled Randomized Phase II Trial Of Gemcitabine And Cisplatin With Or Without The VEGF Inhibitor Bevacizumab (NSC 704865) In Patients With Malignant Mesotheloma.
Latest Information Update: 18 Sep 2021
At a glance
- Drugs Bevacizumab (Primary) ; Cisplatin; Gemcitabine
- Indications Mesothelioma
- Focus Biomarker; Therapeutic Use
- 11 Feb 2014 Biomarkers information updated
- 04 Jun 2012 Results published in the Journal of Clinical Oncology.
- 17 Sep 2010 Actual end date (Aug 2010) added as reported by ClinicalTrials.gov.